Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

The comparative safety of analgesics in older adults with arthritis.

Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S.

Arch Intern Med. 2010 Dec 13;170(22):1968-76. doi: 10.1001/archinternmed.2010.391. Erratum in: Arch Intern Med. 2011 Mar 14;171(5):403.

PMID:
21149752
2.

Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis.

Jones P, Lamdin R.

Clin Drug Investig. 2010;30(7):419-37. doi: 10.2165/11533350-000000000-00000. Review.

PMID:
20527999
4.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
5.

Cyclooxygenase-2 inhibitors and cardiovascular risk.

Solomon SD.

Curr Opin Cardiol. 2006 Nov;21(6):613-7. Review.

PMID:
17053413
6.

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

Moodley I.

Cardiovasc J Afr. 2008 Mar-Apr;19(2):102-7. Review.

7.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
8.

The NSAID dilemma: managing osteoarthritis in high-risk patients.

Roth SH, Anderson S.

Phys Sportsmed. 2011 Sep;39(3):62-74. doi: 10.3810/psm.2011.09.1922. Review.

PMID:
22030942
9.
10.
11.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
12.

4 years after withdrawal of rofecoxib: where do we stand today?

Jaksch W, Dejaco C, Schirmer M.

Rheumatol Int. 2008 Oct;28(12):1187-95. doi: 10.1007/s00296-008-0650-4. Epub 2008 Jul 29. Review.

PMID:
18663451
13.

Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.

Patrício JP, Barbosa JP, Ramos RM, Antunes NF, de Melo PC.

Clin Drug Investig. 2013 Mar;33(3):167-83. doi: 10.1007/s40261-013-0052-6. Review.

PMID:
23338974
14.

Coxibs: is there a benefit when compared to traditional non-selective NSAIDs in postoperative pain management?

Wickerts L, Warrén Stomberg M, Brattwall M, Jakobsson J.

Minerva Anestesiol. 2011 Nov;77(11):1084-98. Epub 2011 May 26. Review.

15.

Opioids for chronic pain: new evidence, new strategies, safe prescribing.

de Leon-Casasola OA.

Am J Med. 2013 Mar;126(3 Suppl 1):S3-11. doi: 10.1016/j.amjmed.2012.11.011. Review.

PMID:
23414718
17.

An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.

Tannenbaum H, Bombardier C, Davis P, Russell AS; Third Canadian Consensus Conference Group.

J Rheumatol. 2006 Jan;33(1):140-57. Epub 2005 Dec 1. Erratum in: J Rheumatol. 2006 Apr;33(4):829. J Rheumatol. 2006 Feb;33(2):440.

PMID:
16331802
18.

[Is there a future for COX-2 inhibitors?].

Yodfat Y.

Harefuah. 2004 Nov;143(11):820-4, 837. Review. Hebrew.

PMID:
15603272
19.

Global safety of coxibs and NSAIDs.

Pham K, Hirschberg R.

Curr Top Med Chem. 2005;5(5):465-73. Review.

PMID:
15974941
20.

[Analgesic effects of cyclooxygenase 2 inhibitors].

Jayr C.

Bull Cancer. 2004 May;91 Suppl 2:S125-31. Review. French.

Supplemental Content

Support Center